Skip to content

Total Splenectomy vs Partial Splenectomy in Non-malignant Hemoglobinopathies : Study Comparing the Effectiveness

Total Splenectomy vs Partial Splenectomy in Non-malignant Hemoglobinopathies : Study Comparing the Effectiveness

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05184647
Enrollment
100
Registered
2022-01-11
Start date
2022-01-16
Completion date
2022-12-30
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Splenectomy; Status

Keywords

Pediatrics, Non-malignant hemoglobinopathies, Comprative effectivness, Partial Splenectomy, Total Splenectomy

Brief summary

Partial splenectomy or total splenectomy are the two surgical treatment of non-malignant hemoglobinoptahie. The aim of this treatment is to decrease transfusion. The main risk is infectious in total splenectomy, that's why partial splenectomy was suggest. But the efficiency of partial splenectomy decrease over time and a totalisation could be mandatory.

Interventions

None listed

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

* Children between 0- 18 years olds * Total or partial splenectomy * Non malignant hémoglobinopathies

Exclusion criteria

\- Total or partial splenectomy outside of non malignant hemoglobinopathies

Design outcomes

Primary

MeasureTime frameDescription
Compared the effectiveness with the number of transfusionDay 1Compared the effectiveness with the number of transfusion after the surgery between total and partial Febrile urinary tract infection was defined as a positive urine examination with a single bacteria with more than 10.5 cfu/mL and more than 10.4 leukocytes/ml associated with fever above 38.5°C and C-reactive protein (CRP) above 50 mg/

Secondary

MeasureTime frameDescription
Number of infectious event in total and partial splenectomyDay 1Number of infectious event in total and partial splenectomy
number of totalisation in partialDay 1number of totalisation in partial

Countries

France

Contacts

Primary ContactNicolas KALFA, MD
n-kalfa@chu-montpellier.fr00334 67 33 87 84
Backup ContactBenoit Tessier, Student
benoitessier@gmail.com4 67 33 87 84

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026